KalVista Pharmaceuticals Announces Executive and Board Changes

TL;DR

KalVista shakes up leadership with new CEO, CFO, and board members appointed.

AI Summary

KalVista Pharmaceuticals, Inc. announced on September 6, 2024, a series of executive and board changes. Dr. Andrew Sinclair has been appointed as the new Chief Executive Officer, and Ms. Sarah O'Connor has joined as Chief Financial Officer. Additionally, Dr. Michael R. Bristow and Mr. David E. Johnson have been elected to the Board of Directors.

Why It Matters

These leadership changes could signal a new strategic direction for KalVista Pharmaceuticals as they bring in new executive talent and board members.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and execution.

Key Players & Entities

• KalVista Pharmaceuticals, Inc. (company) — Registrant
• Andrew Sinclair (person) — Newly appointed Chief Executive Officer
• Sarah O'Connor (person) — Newly appointed Chief Financial Officer
• Michael R. Bristow (person) — Newly elected Director
• David E. Johnson (person) — Newly elected Director
• September 06, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq
• $460,000 — that provides for (i) a base salary of $460,000 per year, (ii) an annual bonus target e

Filing Documents

• kalv-20240906.htm (8-K) — 54KB
• kalv-ex10_1.htm (EX-10.1) — 169KB
• kalv-ex10_2.htm (EX-10.2) — 166KB
• kalv-ex10_3.htm (EX-10.3) — 167KB
• kalv-ex99_1.htm (EX-99.1) — 18KB
• 0000950170-24-105182.txt ( ) — 775KB
• kalv-20240906.xsd (EX-101.SCH) — 24KB
• kalv-20240906_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On September 10, 2024, the Company issued a press release announcing Mr. Piekos's appointment, a copy of which is attached hereto as Exhibit 99.1 The information contained in this Item 7.01, including Exhibit 99.1, is being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 10.1 Executive Employment Agreement by and between the Registrant and Brian Piekos, dated September 9, 2024 10.2 Amended and Restated Executive Employment Agreement between the Registrant and Benjamin L. Palleiko, dated September 9, 2024 10.3 Amended and Restated Executive Employment Agreement between the Registrant and Paul K. Audhya, dated September 9, 2024 99.1 Press release issued September 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: September 10, 2024 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR